EMEA-002007-PIP02-17-M02
Key facts
Invented name |
Libtayo
|
Active substance |
Cemiplimab
|
Therapeutic area |
Oncology
|
Decision number |
P/0179/2022
|
PIP number |
EMEA-002007-PIP02-17-M02
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Regeneron Ireland DAC
E-mail: clinicaltrials@regeneron.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|